{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:23:07Z","timestamp":1793388187171,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008967","name":"Philipps-Universit\u00e4t Marburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008967","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol. Res. Pract."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Parkinson\u2019s disease (PD) multimodal complex treatment (PD-MCT) is an inpatient therapeutic programme specifically designed for patients exhibiting parkinsonian symptoms. Established in Germany, this comprehensive approach addresses the multifaceted challenges associated with the management of PD, particularly in advanced stages or when complications such as motor fluctuations, dyskinesia, or non-motor symptoms become pronounced. The programme integrates pharmacological optimization, physiotherapy, occupational therapy, speech therapy, and psychological support, among other complementary therapies, to enhance patient outcomes holistically. Despite its availability for seventeen years, only seven studies evaluating the effectiveness of PD-MCT have been conducted. In this study we evaluated the effects of PD-MCT with a special focus on gait, hypothesizing an improvement after the treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this single-centre cohort study at a German university hospital we included patients with PD diagnosed by the Movement Disorder Society (MDS) criteria, aged 18\u201385 years, legal capacity to consent and admitted for treatment with PD-MCT. We assessed changes in motor and non-motor symptoms using Wilcoxon\u2019s signed rank test on pre\/post measurements of part III of the motor part of the MDS Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS), the Parkinson\u2019s Disease Questionnaire (PDQ-39) and the Timed Up and Go Test (TUG). As a particular emphasis was placed on gait analysis we objectively measured gait throughout the treatment period using advanced mobile sensor technology and analysed gait speed, stride length and lift height using linear mixed effects models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In our sample of 43 PD patients we found significant improvements in MDS-UPRDRS part III (V\u2009=\u2009679,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001), PDQ-39 (V\u2009=\u2009770,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and TUG (V\u2009=\u2009753.5,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) values. as well as in the assessed gait parameters gait speed (t\u2009=\u200966.44,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), stride length (t\u2009=\u200962.67,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and lift height (t\u2009=\u200928.16,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results underscore the added value of a multimodal inpatient approach, thereby supporting its role as a justified investment in the management of complex PD cases. This work contributes to the expanding body of evidence advocating for integrated, multidisciplinary care models in the treatment of neurodegenerative disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>This study has not been registered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42466-025-00422-y","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T15:18:43Z","timestamp":1756826323000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Multidisciplinary inpatient care for Parkinson\u2019s disease: a single-centre cohort study on improvements in gait, overall motor function, and quality of life"],"prefix":"10.1186","volume":"7","author":[{"given":"Urs","family":"Kleinholdermann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicitas C. J.","family":"M\u00fcgge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziano","family":"Carapezza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Decher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Timmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5403-1959","authenticated-orcid":false,"given":"David J.","family":"Pedrosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"issue":"1","key":"422_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/jamaneurol.2017.3299","volume":"75","author":"ER Dorsey","year":"2018","unstructured":"Dorsey, E. R., & Bloem, B. R. (2018). The Parkinson pandemic\u2014A call to action. JAMA Neurology, 75(1), 9. https:\/\/doi.org\/10.1001\/jamaneurol.2017.3299","journal-title":"JAMA Neurology"},{"issue":"10291","key":"422_CR2","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem, B. R., Okun, M. S., & Klein, C. (2021). Parkinson\u2019s disease. The Lancet, 397(10291), 2284\u20132303. https:\/\/doi.org\/10.1016\/S0140-6736(21)00218-X","journal-title":"The Lancet"},{"issue":"10","key":"422_CR3","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1111\/jgs.12458","volume":"61","author":"NJ Weerkamp","year":"2013","unstructured":"Weerkamp, N. J., Tissingh, G., Poels, P. J. E., Zuidema, S. U., Munneke, M., Koopmans, R. T., C., M., & Bloem, B. R. (2013). Nonmotor symptoms in nursing home residents with parkinson\u2019s disease: Prevalence and effect on quality of life. Journal of the American Geriatrics Society, 61(10), 1714\u20131721. https:\/\/doi.org\/10.1111\/jgs.12458","journal-title":"Journal of the American Geriatrics Society"},{"key":"422_CR4","doi-asserted-by":"publisher","unstructured":"Kumaresan, M., & Khan, S. (2021). Spectrum of Non-Motor symptoms in parkinson\u2019s disease. Cureus. https:\/\/doi.org\/10.7759\/cureus.13275","DOI":"10.7759\/cureus.13275"},{"issue":"7","key":"422_CR5","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1056\/NEJM196702162760703","volume":"276","author":"GC Cotzias","year":"1967","unstructured":"Cotzias, G. C., Van Woert, M. H., & Schiffer, L. M. (1967). Aromatic amino acids and modification of parkinsonism. New England Journal of Medicine, 276(7), 374\u2013379. https:\/\/doi.org\/10.1056\/NEJM196702162760703","journal-title":"New England Journal of Medicine"},{"issue":"5942","key":"422_CR6","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1136\/bmj.4.5942.442","volume":"4","author":"DB Calne","year":"1974","unstructured":"Calne, D. B., Teychenne, P. F., Claveria, L. E., Eastman, R., Greenacre, J. K., & Petrie, A. (1974). Bromocriptine in Parkinsonism BMJ, 4(5942), 442\u2013444. https:\/\/doi.org\/10.1136\/bmj.4.5942.442","journal-title":"Bromocriptine in Parkinsonism BMJ"},{"issue":"20","key":"422_CR7","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1212\/WNL.0000000000012868","volume":"97","author":"T Pringsheim","year":"2021","unstructured":"Pringsheim, T., Day, G. S., Smith, D. B., Rae-Grant, A., Licking, N., Armstrong, M. J., De Bie, R. M. A., Roze, E., Miyasaki, J. M., Hauser, R. A., Espay, A. J., Martello, J. P., Gurwell, J. A., Billinghurst, L., Sullivan, K., Fitts, M. S., Cothros, N., Hall, D. A., Rafferty, M., & Lang, A. E. (2021). Dopaminergic therapy for motor symptoms in early Parkinson disease practice guideline summary: A report of the AAN guideline subcommittee. Neurology, 97(20), 942\u2013957. https:\/\/doi.org\/10.1212\/WNL.0000000000012868","journal-title":"Neurology"},{"issue":"4917","key":"422_CR8","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1126\/science.2502843","volume":"245","author":"JW Tetrud","year":"1989","unstructured":"Tetrud, J. W., & Langston, J. W. (1989). The effect of deprenyl (Selegiline) on the natural history of parkinson\u2019s disease. Science, 245(4917), 519\u2013522. https:\/\/doi.org\/10.1126\/science.2502843","journal-title":"Science"},{"issue":"1","key":"422_CR9","doi-asserted-by":"publisher","first-page":"16024","DOI":"10.1038\/npjparkd.2016.24","volume":"3","author":"MM Kurtis","year":"2017","unstructured":"Kurtis, M. M., Rajah, T., Delgado, L. F., & Dafsari, H. S. (2017). The effect of deep brain stimulation on the non-motor symptoms of parkinson\u2019s disease: A critical review of the current evidence. Npj Parkinson\u2019s Disease, 3(1), 16024. https:\/\/doi.org\/10.1038\/npjparkd.2016.24","journal-title":"Npj Parkinson\u2019s Disease"},{"issue":"4","key":"422_CR10","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41582-019-0145-9","volume":"15","author":"P Limousin","year":"2019","unstructured":"Limousin, P., & Foltynie, T. (2019). Long-term outcomes of deep brain stimulation in Parkinson disease. Nature Reviews Neurology, 15(4), 234\u2013242. https:\/\/doi.org\/10.1038\/s41582-019-0145-9","journal-title":"Nature Reviews Neurology"},{"issue":"1\u20136","key":"422_CR11","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1159\/000100803","volume":"50","author":"AL Benabid","year":"1987","unstructured":"Benabid, A. L., Pollak, P., Louveau, A., Henry, S., & De Rougemont, J. (1987). Combined (Thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Stereotactic and Functional Neurosurgery, 50(1\u20136), 344\u2013346. https:\/\/doi.org\/10.1159\/000100803","journal-title":"Stereotactic and Functional Neurosurgery"},{"issue":"12","key":"422_CR12","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1080\/03007995.2018.1502165","volume":"34","author":"A Antonini","year":"2018","unstructured":"Antonini, A., Stoessl, A. J., Kleinman, L. S., Skalicky, A. M., Marshall, T. S., Sail, K. R., Onuk, K., & Odin, P. L. A. (2018). Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced parkinson\u2019s disease: A multi-country Delphi-panel approach. Current Medical Research and Opinion, 34(12), 2063\u20132073. https:\/\/doi.org\/10.1080\/03007995.2018.1502165","journal-title":"Current Medical Research and Opinion"},{"issue":"1","key":"422_CR13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41531-022-00320-z","volume":"8","author":"MC Gonzalez","year":"2022","unstructured":"Gonzalez, M. C., Dalen, I., Maple-Gr\u00f8dem, J., Tysnes, O. B., & Alves, G. (2022). Parkinson\u2019s disease clinical milestones and mortality. Npj Parkinson\u2019s Disease, 8(1), 58. https:\/\/doi.org\/10.1038\/s41531-022-00320-z","journal-title":"Npj Parkinson\u2019s Disease"},{"issue":"7","key":"422_CR14","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S1474-4422(20)30064-8","volume":"19","author":"BR Bloem","year":"2020","unstructured":"Bloem, B. R., Henderson, E. J., Dorsey, E. R., Okun, M. S., Okubadejo, N., Chan, P., Andrejack, J., Darweesh, S. K. L., & Munneke, M. (2020). Integrated and patient-centred management of parkinson\u2019s disease: A network model for reshaping chronic neurological care. The Lancet Neurology, 19(7), 623\u2013634. https:\/\/doi.org\/10.1016\/S1474-4422(20)30064-8","journal-title":"The Lancet Neurology"},{"issue":"8","key":"422_CR15","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1007\/s00115-024-01666-w","volume":"95","author":"R Scherbaum","year":"2024","unstructured":"Scherbaum, R., & T\u00f6nges, L. (2024). Multidisziplin\u00e4re komplextherapie der Parkinson-Krankheit: Eckpfeiler einer individualisierten behandlung. Der Nervenarzt, 95(8), 704\u2013713. https:\/\/doi.org\/10.1007\/s00115-024-01666-w","journal-title":"Der Nervenarzt"},{"key":"422_CR16","first-page":"24","volume":"5","author":"M Knop","year":"2017","unstructured":"Knop, M., S\u00e4mann, P. G., & Keck, M. E. (2017). Parkinson-Komplextherapie am Max-Planck-Institut f\u00fcr psychiatrie: Ein multimodales, flexibles Station\u00e4res therapieprogramm f\u00fcr kritische krankheitsphasen. Psychiatr Neurol, 5, 24\u201329.","journal-title":"Psychiatr Neurol"},{"key":"422_CR17","doi-asserted-by":"publisher","unstructured":"H\u00f6glinger, G., German Parkinson\u2019s Guidelines Committee, & Trenkwalder, C. (2024). Diagnosis and treatment of Parkinson\u00b4s disease (guideline of the German Society for Neurology). Neurological research and practice, 6(1), 30. https:\/\/doi.org\/10.1186\/s42466-024-00325-4","DOI":"10.1186\/s42466-024-00325-4"},{"issue":"2","key":"422_CR18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3390\/cells8020151","volume":"8","author":"D Richter","year":"2019","unstructured":"Richter, D., Bartig, D., Muhlack, S., Hartelt, E., Scherbaum, R., Katsanos, A. H., M\u00fcller, T., Jost, W., Ebersbach, G., Gold, R., Krogias, C., & T\u00f6nges, L. (2019). Dynamics of parkinson\u2019s disease multimodal complex treatment in Germany from 2010\u20132016: Patient characteristics, access to treatment, and formation of regional centers. Cells, 8(2), 151. https:\/\/doi.org\/10.3390\/cells8020151","journal-title":"Cells"},{"issue":"11","key":"422_CR19","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.3390\/brainsci11111460","volume":"11","author":"KG Heimrich","year":"2021","unstructured":"Heimrich, K. G., & Prell, T. (2021). Short- and long-term effect of parkinson\u2019s disease multimodal complex treatment. Brain Sciences, 11(11), 1460. https:\/\/doi.org\/10.3390\/brainsci11111460","journal-title":"Brain Sciences"},{"issue":"6","key":"422_CR20","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.3390\/jcm9061874","volume":"9","author":"E Hartelt","year":"2020","unstructured":"Hartelt, E., Scherbaum, R., Kinkel, M., Gold, R., Muhlack, S., & T\u00f6nges, L. (2020). Parkinson\u2019s disease multimodal complex treatment (PD-MCT): Analysis of therapeutic effects and predictors for improvement. Journal of Clinical Medicine, 9(6), 1874. https:\/\/doi.org\/10.3390\/jcm9061874","journal-title":"Journal of Clinical Medicine"},{"issue":"1","key":"422_CR21","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12883-022-02647-9","volume":"22","author":"L Wagner","year":"2022","unstructured":"Wagner, L., Hauptmann, B., Hoffmann, A. K., Jochems, N., Schmeier, B., Schrader, A., Kohlmann, T., & Deck, R. (2022). Evaluation of an individualized, tablet-based physiotherapy training programme for patients with parkinson\u2019s disease: The ParkProTrain study, a quasi-randomised controlled trial. BMC Neurology, 22(1), 176. https:\/\/doi.org\/10.1186\/s12883-022-02647-9","journal-title":"BMC Neurology"},{"issue":"1","key":"422_CR22","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/mdc3.13578","volume":"10","author":"K Ziegler","year":"2023","unstructured":"Ziegler, K., Messner, M., Paulig, M., Starrost, K., Reuschenbach, B., Fietzek, U. M., & Ceballos-Baumann, A. O. (2023). Activities of daily living are improved by inpatient multimodal complex treatment for PD\u2014A real\u2010world cohort study. Movement Disorders Clinical Practice, 10(1), 42\u201354. https:\/\/doi.org\/10.1002\/mdc3.13578","journal-title":"Movement Disorders Clinical Practice"},{"key":"422_CR23","doi-asserted-by":"publisher","first-page":"175628642412771","DOI":"10.1177\/17562864241277157","volume":"17","author":"J Oppermann","year":"2024","unstructured":"Oppermann, J., Tschentscher, V., Welzel, J., Geritz, J., Hansen, C., Gold, R., Maetzler, W., Scherbaum, R., & T\u00f6nges, L. (2024). Clinical and device-based predictors of improved experience of activities of daily living after a multidisciplinary inpatient treatment for people with parkinson\u2019s disease: A cohort study. Therapeutic Advances in Neurological Disorders, 17, 17562864241277157. https:\/\/doi.org\/10.1177\/17562864241277157","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"4","key":"422_CR24","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1007\/s00415-019-09657-7","volume":"267","author":"R Scherbaum","year":"2020","unstructured":"Scherbaum, R., Hartelt, E., Kinkel, M., Gold, R., Muhlack, S., & T\u00f6nges, L. (2020). Parkinson\u2019s disease multimodal complex treatment improves motor symptoms, depression and quality of life. Journal of Neurology, 267(4), 954\u2013965. https:\/\/doi.org\/10.1007\/s00415-019-09657-7","journal-title":"Journal of Neurology"},{"issue":"03","key":"422_CR25","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1055\/a-2449-1461","volume":"44","author":"K Ziegler","year":"2025","unstructured":"Ziegler, K., Fietzek, U. M., & Ceballos-Baumann, A. O. (2025). Multimodale Therapieangebote Bei der Parkinson-Krankheit. Nervenheilkunde, 44(03), 86\u201397. https:\/\/doi.org\/10.1055\/a-2449-1461","journal-title":"Nervenheilkunde"},{"issue":"s1","key":"422_CR26","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.3233\/JPD-230271","volume":"14","author":"E Steendam-Oldekamp","year":"2024","unstructured":"Steendam-Oldekamp, E., & van Laar, T. (2024). The effectiveness of inpatient rehabilitation in parkinson\u2019s disease: A systematic review of recent studies. Journal of Parkinson\u2019s Disease, 14(s1), S93\u2013S112. https:\/\/doi.org\/10.3233\/JPD-230271","journal-title":"Journal of Parkinson\u2019s Disease"},{"issue":"6","key":"422_CR27","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1080\/14737175.2020.1771184","volume":"20","author":"SC Lidstone","year":"2020","unstructured":"Lidstone, S. C., Bayley, M., & Lang, A. E. (2020). The evidence for multidisciplinary care in parkinson\u2019s disease. Expert Review of Neurotherapeutics, 20(6), 539\u2013549. https:\/\/doi.org\/10.1080\/14737175.2020.1771184","journal-title":"Expert Review of Neurotherapeutics"},{"issue":"11","key":"422_CR28","doi-asserted-by":"publisher","first-page":"6067","DOI":"10.1007\/s00415-022-11257-x","volume":"269","author":"R Scherbaum","year":"2022","unstructured":"Scherbaum, R., Moewius, A., Oppermann, J., Geritz, J., Hansen, C., Gold, R., Maetzler, W., & T\u00f6nges, L. (2022). Parkinson\u2019s disease multimodal complex treatment improves gait performance: An exploratory wearable digital device-supported study. Journal of Neurology, 269(11), 6067\u20136085. https:\/\/doi.org\/10.1007\/s00415-022-11257-x","journal-title":"Journal of Neurology"},{"issue":"12","key":"422_CR29","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., Halliday, G., Goetz, C. G., Gasser, T., Dubois, B., Chan, P., Bloem, B. R., Adler, C. H., & Deuschl, G. (2015). MDS clinical diagnostic criteria for parkinson\u2019s disease: MDS-PD clinical diagnostic criteria. Movement Disorders, 30(12), 1591\u20131601. https:\/\/doi.org\/10.1002\/mds.26424","journal-title":"Movement Disorders"},{"issue":"1","key":"422_CR30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s42466-023-00263-7","volume":"5","author":"F M\u00fcgge","year":"2023","unstructured":"M\u00fcgge, F., Kleinholdermann, U., Heun, A., Ollenschl\u00e4ger, M., Hannink, J., & Pedrosa, D. J. (2023). Subthalamic 85 hz deep brain stimulation improves walking pace and stride length in Parkinson\u2019s disease patients. Neurological Research and Practice, 5(1), 33. https:\/\/doi.org\/10.1186\/s42466-023-00263-7","journal-title":"Neurological Research and Practice"},{"issue":"3","key":"422_CR31","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/BF02260863","volume":"4","author":"V Peto","year":"1995","unstructured":"Peto, V., Jenkinson, C., Fitzpatrick, R., & Greenhall, R. (1995). The development and validation of a short measure of functioning and well being for individuals with parkinson\u2019s disease. Quality of Life Research, 4(3), 241\u2013248. https:\/\/doi.org\/10.1007\/BF02260863","journal-title":"Quality of Life Research"},{"issue":"2","key":"422_CR32","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1532-5415.1991.tb01616.x","volume":"39","author":"D Podsiadlo","year":"1991","unstructured":"Podsiadlo, D., & Richardson, S. (1991). The timed up & go: A test of basic functional mobility for frail elderly persons. Journal of the American Geriatrics Society, 39(2), 142\u2013148. https:\/\/doi.org\/10.1111\/j.1532-5415.1991.tb01616.x","journal-title":"Journal of the American Geriatrics Society"},{"key":"422_CR33","doi-asserted-by":"publisher","unstructured":"Goetz, C. G., Tilley, B. C., Shaftman, S. R., Stebbins, G. T., Fahn, S., Martinez-Martin,P., Poewe, W., Sampaio, C., Stern, M. B., Dodel, R., Dubois, B., Holloway, R., Jankovic,J., Kulisevsky, J., Lang, A. E., Lees, A., Leurgans, S., LeWitt, P. A., Nyenhuis,D., \u2026 Movement Disorder Society UPDRS Revision Task Force. (2008). Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS):Scale presentation and clinimetric testing results. Movement Disorders: Official Journal of the Movement Disorder Society, 23(15), 2129\u20132170. https:\/\/doi.org\/10.1002\/mds.22340.","DOI":"10.1002\/mds.22340"},{"issue":"3","key":"422_CR34","doi-asserted-by":"publisher","first-page":"6419","DOI":"10.3390\/s150306419","volume":"15","author":"J Barth","year":"2015","unstructured":"Barth, J., Oberndorfer, C., Pasluosta, C., Sch\u00fclein, S., Gassner, H., Reinfelder, S., Kugler, P., Schuldhaus, D., Winkler, J., Klucken, J., & Eskofier, B. (2015). Stride segmentation during free walk movements using multi-dimensional subsequence dynamic time warping on inertial sensor data. Sensors (Basel, Switzerland), 15(3), 6419\u20136440. https:\/\/doi.org\/10.3390\/s150306419","journal-title":"Sensors (Basel, Switzerland)"},{"key":"422_CR35","doi-asserted-by":"publisher","unstructured":"Hannink, J., Ollenschl\u00e4ger, M., Kluge, F., Roth, N., Klucken, J., & Eskofier, B. M. (2017). Benchmarking foot trajectory estimation methods for mobile gait analysis. Sensors, 17(9), 1940. https:\/\/doi.org\/10.3390\/s17091940","DOI":"10.3390\/s17091940"},{"key":"422_CR36","unstructured":"R Core Team (2018). R: A language and environment for statistical computing. R Foundation for Statistical Computing. https:\/\/www.R-project.org\/"},{"issue":"4","key":"422_CR37","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/ageing\/30.4.299","volume":"30","author":"V Peto","year":"2001","unstructured":"Peto, V. (2001). Determining minimally important differences for the PDQ-39 parkinson\u2019s disease questionnaire. Age and Ageing, 30(4), 299\u2013302. https:\/\/doi.org\/10.1093\/ageing\/30.4.299","journal-title":"Age and Ageing"},{"issue":"12","key":"422_CR38","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.parkreldis.2015.10.006","volume":"21","author":"K Horv\u00e1th","year":"2015","unstructured":"Horv\u00e1th, K., Aschermann, Z., \u00c1cs, P., Deli, G., Janszky, J., Komoly, S., Bal\u00e1zs, \u00c9., Tak\u00e1cs, K., Kar\u00e1di, K., & Kov\u00e1cs, N. (2015). Minimal clinically important difference on the motor examination part of MDS-UPDRS. Parkinsonism & Related Disorders, 21(12), 1421\u20131426. https:\/\/doi.org\/10.1016\/j.parkreldis.2015.10.006","journal-title":"Parkinsonism & Related Disorders"},{"key":"422_CR39","doi-asserted-by":"publisher","unstructured":"Santos Garc\u00eda, D., De Deus Fonticoba, T., Su\u00e1rez Castro, E., Borru\u00e9, C., Mata, M.,Solano Vila, B., Cots Foraster, A., \u00c1lvarez Sauco, M., Rodr\u00edguez P\u00e9rez, A. B., Vela,L., Mac\u00edas, Y., Escalante, S., Esteve, P., Revert\u00e9 Villarroya, S., Cubo, E., Casas,E., Arnaiz, S., Carrillo Padilla, F., Pueyo Morlans, M., \u2026 Villar, M. D. (2019). Non-motor symptoms burden, mood, and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson\u2019s disease patients: Results from the COPPADIS study cohort. Parkinsonism & Related Disorders, 66, 151\u2013157. https:\/\/doi.org\/10.1016\/j.parkreldis.2019.07.031.","DOI":"10.1016\/j.parkreldis.2019.07.031"},{"issue":"4","key":"422_CR40","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1007\/s11845-024-03673-x","volume":"193","author":"P Cronin","year":"2024","unstructured":"Cronin, P., Collins, L. M., & Sullivan, A. M. (2024). Impacts of gait freeze on quality of life in parkinson\u2019s disease, from the perspectives of patients and their carers. Irish Journal of Medical Science (1971 -), 193(4), 2041\u20132050. https:\/\/doi.org\/10.1007\/s11845-024-03673-x","journal-title":"Irish Journal of Medical Science (1971 -)"},{"issue":"7","key":"422_CR41","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S1474-4422(19)30044-4","volume":"18","author":"A Mirelman","year":"2019","unstructured":"Mirelman, A., Bonato, P., Camicioli, R., Ellis, T. D., Giladi, N., Hamilton, J. L., Hass, C. J., Hausdorff, J. M., Pelosin, E., & Almeida, Q. J. (2019). Gait impairments in parkinson\u2019s disease. The Lancet Neurology, 18(7), 697\u2013708. https:\/\/doi.org\/10.1016\/S1474-4422(19)30044-4","journal-title":"The Lancet Neurology"},{"issue":"21","key":"422_CR42","doi-asserted-by":"publisher","first-page":"8971","DOI":"10.3390\/s23218971","volume":"23","author":"E Bianchini","year":"2023","unstructured":"Bianchini, E., Galli, S., Alborghetti, M., De Carolis, L., Zampogna, A., Hansen, C., Vuillerme, N., Suppa, A., & Pontieri, F. E. (2023). Four days are enough to provide a reliable daily step count in mild to moderate parkinson\u2019s disease through a commercial smartwatch. Sensors (Basel, Switzerland), 23(21), 8971. https:\/\/doi.org\/10.3390\/s23218971","journal-title":"Sensors (Basel, Switzerland)"},{"issue":"1","key":"422_CR43","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41531-021-00171-0","volume":"7","author":"A Atrsaei","year":"2021","unstructured":"Atrsaei, A., Corr\u00e0, M. F., Dadashi, F., Vila-Ch\u00e3, N., Maia, L., Mariani, B., Maetzler, W., & Aminian, K. (2021). Gait speed in clinical and daily living assessments in parkinson\u2019s disease patients: Performance versus capacity. Npj Parkinson\u2019s Disease, 7(1), 24. https:\/\/doi.org\/10.1038\/s41531-021-00171-0","journal-title":"Npj Parkinson\u2019s Disease"},{"issue":"2","key":"422_CR44","doi-asserted-by":"publisher","first-page":"e0246528","DOI":"10.1371\/journal.pone.0246528","volume":"16","author":"M Sica","year":"2021","unstructured":"Sica, M., Tedesco, S., Crowe, C., Kenny, L., Moore, K., Timmons, S., Barton, J., O\u2019Flynn, B., & Komaris, D. S. (2021). Continuous home monitoring of parkinson\u2019s disease using inertial sensors: A systematic review. PloS One, 16(2), e0246528. https:\/\/doi.org\/10.1371\/journal.pone.0246528","journal-title":"PloS One"}],"container-title":["Neurological Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-025-00422-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42466-025-00422-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-025-00422-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T15:18:46Z","timestamp":1756826326000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurolrespract.biomedcentral.com\/articles\/10.1186\/s42466-025-00422-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["422"],"URL":"https:\/\/doi.org\/10.1186\/s42466-025-00422-y","relation":{},"ISSN":["2524-3489"],"issn-type":[{"value":"2524-3489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"assertion":[{"value":"4 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study adhered to the Declaration of Helsinki and received approval from the Research Ethics Committee of the Philipps University, Germany (reference number 86\/21).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Urs Kleinholdermann, Lukas Decher, Tiziano Carapezza and Felicitas M\u00fcgge have no competing interests to report. Lars Timmermann LT has received payments as a consultant for Boston Scientific; honoraria as a speaker on symposia sponsored by UCB, Desitin, Boston Scientific, AbbVie, Novartis, GlaxoSmithKline, Neuraxpharm, Teva, the Movement Disorders Society und DIAPLAN. The institution of LT, not LT personally, received funding by Boston Scientific, the German Research Foundation, the German Ministry of Education and Research, the Otto Loewi Foundation and the Deutsche Parkinson Vereinigung, outside the submitted work. Neither LT nor any member of his family holds stocks, stock options, patents or financial interests in any of the above-mentioned companies or their competitors. LT serves as the president of the German Neurological Society without any payment or any income. David Pedrosa received honoraria as a speaker at symposia sponsored by AbbVie Inc., Bayer, Bial, Boston Scientific Corp., Esteve Pharmaceuticals, Medtronic and Zambon. He received consultancy fees from AbbVie Inc., Bial, Boston Scientific Corp., Bayer, and Desitin, and he was awarded a scientific grant from Boston Scientific Corp. for a project entitled \u201cSensor-based Optimization of Deep Brain Stimulation Settings in Parkinson\u2019s Disease\u201d (COMPARE-DBS: Computerized Parameter Optimization of Deep Brain Stimulation in Idiopathic Parkinson\u2019s Syndrome). Lastly, David Pedrosa had his travel expenses reimbursed by Bial, Desitin, Esteve Pharmaceuticals GmbH, and Boston Scientific Corp. for conference participation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}